Received Apr 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | UNK | U8510AA | — |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | UNK | 2164395 | — |
HCP called to report a TE for ROTATEQ and VAXELIS. Products were administered.; No adverse effects reported; This spontaneous report was received from a consumer referring to a 2-months-old female patient. The patient's pertinent medical history, known drug allergies or reactions, and concomitant therapies were not reported. On an unspecified date, the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) as prophylaxis (lot #2164395 has been verified to be valid, expiration date: 22-MAR-2027) (dose, frequency, route of administration, and administration site were not reported); it was co-administered on the same unspecified date, with Diphtheria and Tetanus Toxoids, and Acellular Pertussis, Inactivated Poliovirus, Hib Conjugate (MPC) and rHBV Vaccine (VAXELIS) 0.5 mL injection as prophylaxis (lot #U8510AA has been verified to be valid, expiration date: 30-APR-2028) (dose, frequency, route of administration, and administration site were not reported); both vaccines were administered after a temperature excursion (Product storage error). No adverse effects reported (No adverse event).